Cerebrospinal Fluid Neurogranin Correlates with Markers of Neurodegeneration
Levels of CSF biomarker neurogranin correlate with imaging measures of synaptic integrity in ADNI cohort.
589 RESULTS
Sort By:
Levels of CSF biomarker neurogranin correlate with imaging measures of synaptic integrity in ADNI cohort.
Neurogranin could be a promising early CSF biomarker of Alzheimer’s disease.
Postmortem pathology confirms that some people who were diagnosed with AD during life had no appreciable amyloid in the brain, leaving researchers to puzzle over what caused their cognitive decline.
Scientists struggle to understand neurodegeneration in the SNAP syndrome.
The synaptic protein abounds in the cerebrospinal fluid of AD patients and in those in the prodromal phase of the disease.
Can proteins in the cerebrospinal fluid help tell movement disorders apart and predict who will develop dementia?
Variability still plagues CSF biomarker measurements, but automated systems offer hope of a diagnostic assay.
At AAIC, new data on three anti-Aβ antibodies reinforced a sense of hope that Aβ immunotherapy may yet work out. Challenges with each antibody notwithstanding, all four leading candidates, including crenezumab, are now in Phase 3.
Probing this this Alzheimer’s risk factor, scientists find a novel variant, but no consensus yet on how this cell surface receptor increases risk for disease.
In some people, proteins in the cerebrospinal fluid trend toward an Alzheimer’s-like profile as early as age 45.
A behavioral variant of Alzheimer’s disease is not accompanied by shrinking of the frontal cortex. Rather, these patients have similar patterns of atrophy as those with typical AD.
In children as young as 9 who carry a presenilin 1 mutation, researchers detect subtle functional and structural brain changes.
Neuron-derived vesicles floating in the blood carry protein signatures that flag lysosomal dysfunction. Could they detect preclinical Alzheimer’s disease?
Levels of a neuronal protein in blood correlated with rate of decline in two U.K. cohorts.
In separate studies, researchers propose that high CSF ferritin and D-serine could become biomarkers to predict declining cognition in Alzheimer’s disease.